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The CD163 scavenger receptor pathway for Hb:Hp complexes is an essential mechanism of protection against the toxicity of
extracellular hemoglobin (Hb), which can accumulate in the vasculature and within tissues during hemolysis. Chloroquine is
a lysosomotropic agent, which has been extensively used as an antimalarial drug in the past, before parasite resistance started
to limit its efficacy in most parts of the world. More recent use of chloroquine is related to its immunomodulatory activity in
patients with autoimmune diseases, which may also involve hemolytic disease components. In this study we examined the effects
of chloroquine on the human Hb clearance pathway. For this purpose we developed a new mass-spectrometry-based method to
specifically quantify intracellular Hb peptides within the endosomal-lysosomal compartment by single reactionmonitoring (SRM).
We found that chloroquine exposure impairs trafficking of Hb:Hp complexes through the endosomal-lysosomal compartment after
internalization by CD163. Relative quantification of intracellular Hb peptides by SRM confirmed that chloroquine blocked cellular
Hb:Hp catabolism.This effect suppressed the cellular heme-oxygenase-1 (HO-1) response and shiftedmacrophage iron homeostasis
towards inappropriately high expression of the transferrin receptor with concurrent inhibition of ferroportin expression. A
functional deficiency of Hb detoxification and heme-iron recycling may therefore be an adverse consequence of chloroquine
treatment during hemolysis.
1. Introduction
Extracellular hemoglobin (Hb) is the pathophysiologic con-
sequence of hemolysis and is not innocuous [1].The injurious
impact of freeHb has been ascribed to heme-driven oxidative
processes and vascular dysfunction. A functionally intact
clearance pathway is thus essential for rapid and efficient
elimination and detoxification of free Hb and prevention of
its deleterious effects [2, 3].
The CD163 receptor facilitates endocytosis of free Hb and
Hb-haptoglobin (Hb:Hp) complexes for intralysosomal pro-
cessing by bloodmonocytes and resident tissuemacrophages,
primarily in the liver and spleen [4–6]. When eventually
delivered to the cytoplasm, the globin-free heme is degraded
by heme-oxygenase-1 (HO-1) [7, 8]. A diminished pool of
monocytes/macrophages, as well as any loss of lysosomal
function or lack of HO-1 activity, may therefore compromise
physiologic Hb detoxification, increasing the likelihood of
pathology [9, 10].
Chloroquine is a lysosomotropic weak base and accumu-
lateswithin acidic cellular compartments.Thepharmacologic
action of chloroquine includes an increase in intralysosomal
pH, preventing fusion of endosomes and lysosomes, and,
consequently, disruption of intracellular trafficking [11–13].
Historically, this agent was widely used for the treatment of
malaria—a prototypic hemolytic condition. The efficacy of
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chloroquine as an antimalarial drug is owed to inhibition
of heme catabolism in plasmodium parasites. By blocking
polymerization ofHb-derived ferriprotoporphyrin IX, highly
toxic heme-chloroquine complexes accumulate, thus limiting
parasite survival [14]. In contrast, preserving theHb clearance
pathway in malaria infected patients is critical. Oxidative
heme toxicity to the blood-brain barrier has been intimately
linked to some of the most severe cerebral complications of
this disease [15], and efficient Hb-iron recycling is critical to
support erythropoiesis during severe anemia, which is one
of the major worldwide causes of malaria death [16–18]. It is
so far not known whether chloroquine could impair the Hb
clearance pathway of human macrophages.
Although chloroquine has been largely abandoned as an
antimalarial agent due to widespread emergence of resistant
parasitic strains and availability of alternative medications
[19, 20], clinical interest was regained in recent years, based
on its utility as an effective immunomodulator. Chloroquine
and its hydroxyl derivative, hydroxychloroquine, are now
widely used as adjuncts in treatment of autoimmune dis-
eases [21, 22]. However, hemolytic anemia is a notable and
frequent manifestation in autoimmunity, such as in patients
with systemic lupus erythematodes (SLEs). The potential
drawbacks of chloroquine therapy, relative to impeded Hb
detoxification, remain unknown and could overshadow the
protective immunomodulatory benefits in some patients with
a significant hemolytic disease component.
For the present study, we developed a new mass-
spectrometry-based quantification method to track directly
CD163 mediated uptake of Hb:Hp into lysosomes and sub-
sequent decay processes. We found that chloroquine treat-
ment resulted in intracellular Hb trapping, abolished HO-1
expression, and suppression of the adaptive iron metabolism
response. Our results suggest that chloroquine interferes
with the hemoglobin scavenger pathway, potentially compro-
mising efficient Hb clearance and aggravating ill effects of
extracellular Hb.
2. Results
2.1. Quantification of Internalized Hb Peptides Using Sin-
gle Reaction Monitoring (SRM). We developed a protein-
targeted single reaction monitoring (SRM) method for
quantifying cell associated Hb by mass-spectrometry. The
method is based on the sequence-specific identification and
label-free quantification of paired peptide precursor- and
fragment-ion masses, also known as transitions. Definitive
transitions to be quantifiedwere selected according to in silico
peptide characteristics, inspection of relative peak intensities
of different transitions, and retention time alignment of
SRM signals. As such, we monitored three Hb peptides
with at least three fragment ions per peptide. Optimal SRM
signals were obtained for the following three Hb peptides:
SAVTALWGK (m/z 466.76), MFLSFPTTK (m/z 536.27), and
LLVVYPWTQR (m/z 637.83).
In Figure 1, representative ion chromatograms of precur-
sors and fragment ions are shown. Note that fragment ions
of the same precursor peptide coelute at the same retention
time. The relative precursor-ion quantity was calculated as
the sum of the peak areas of all related fragment-ion chro-
matograms and was assumed to correlate with the respec-
tive Hb peptide quantity being present in the endosomal-
lysosomal compartment.
2.2. Chloroquine Promotes Intracellular Hb Accumulation.
Figure 2(a) shows representative CD163-transduced HEK-
293 cell pellets obtained after exposure of the cells to Hb:Hp
(2mg/mL) for 12 hours. We have previously reported that
the CD163-HEK-293 cell is a valuable model to study Hb
endocytosis and subsequent cellular responses in vitro [5, 7].
CD163-HEK-293 cells treated with chloroquine (10 𝜇M)
30min before and during Hb:Hp exposure clearly differed
in appearance from control cells. The red-brown color of
chloroquine-treated cells indicated greater accumulation of
heme, as opposed to those not pretreated. This impression
could be substantiated by spectrophotometric analysis of the
lysed cell pellets which shows a significant Hb absorbance
component in chloroquine-treated cells with characteristic
absorbance peaks at 540 nm and 575 nm but much less than
in control cells (insert in Figure 2(b)). In addition a significant
absorption peak was detected at 630 nm, which suggests
that a fraction of Hb is oxidized to metHb (Fe3+) after
endocytosis within the acidic and proteolytic endolysosomal
compartment (not shown). In Figure 2(b), the relative inten-
sity profiles of SRM-trapped fragment ions is depicted for one
representative Hb peptide. Compared with control samples,
this analysis indicates a higher globin protein abundance in
the Hb plus chloroquine-treated CD163-HEK-293 cell lysates
compared to cells that were exposed to Hb in the absence
of chloroquine. Collectively, the increased SRM signal in
parallel to the brown appearance of the cell pellets confirms
that not only heme but also the protein component (globin)
of Hbmassively accumulates in the chloroquine-treated cells.
2.3. Chloroquine Limits Intracellular Hb Clearance without
Altering Cellular Uptake Capacity. We further addressed the
question of whether chloroquine modifies CD163 medi-
ated Hb uptake capacity or whether it interferes with the
subsequent intracellular degradation pathway of Hb. The
fluorescence Hb:Hp uptake assay shown in Figure 3(a) shows
that the uptake capacity of the chloroquine-treated cells
within the first 30min of incubation is equal to control
cells, indicating that the accumulation of Hb observed in
chloroquine-treated cells must be the result of a diminished
Hb degradation, rather than increasedHb uptake. Figure 3(b)
shows the SRM-determined decay of the endocytosed Hb
peptides in chloroquine and control cell populations. After
incubationwithHb:Hp (2mg/mL for 12 hours), the cells were
washed with phosphate-buffered saline (PBS) containing
EDTA to remove noninternalized Hb. Cell samples were
either lyzed immediately after washing (0-hour sample) or
further incubated at 37∘C and lysed after 180 minutes to
quantify intracellular Hb peptides relative to the 0-hour
samples. While we observed a considerable decrease of Hb
peptides in control cells, Hb elimination was blocked by
chloroquine treatment. Therefore, our results suggest that
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Figure 1: SRM of Hb peptides. (a) Amino acid sequences of the alpha and beta chains of Hb. The selected peptides are indicated as bold text
(one peptide in the alpha chain, two peptides in the beta chain). (b) Elution chromatography profiles of the three Hb peptides (SAVTALWGK,
MFLSFPTTK, and LLVVYPWTQR). (c) Transition profiles of precursor and fragment ions of SAVTALWGK peptide coeluting at 32.96min.
chloroquine impairs elimination of Hb by interfering with
lysosomal Hb degradation.
2.4. Chloroquine Inhibits HO-1 Expression and Creates a
State of Relative Intracellular Iron Deprivation. Heme detox-
ification relies primarily on inducible HO-1 enzyme, which
enables degradation of Hb to iron, bilirubin, and CO [23, 24].
With addition of chloroquine, the strong induction of HO-1
expression, that is, normally observed upon Hb:Hp exposure
of CD163-HEK-293 cells, is suppressed at the mRNA and
protein levels (Figure 4(a)). We confirmed this chloroquine
effect also in human peripheral blood monocyte derived
macrophages (Figure 4(b)). Also in this cell type, which
represents the natural Hb clearance compartment in human,
HO-1 induction by Hb:Hp was suppressed by chloroquine.
By limitingHb:Hp triggeredHO-1 expression and cellular
heme metabolism, chloroquine could profoundly modify
macrophage iron homeostasis. We found that exposure to
chloroquine in the absence of Hb stimulated mRNA induc-
tion of the transferrin receptor (the principal iron importer)
(Figure 4(c)). This implies that under the pharmacologic
influence of chloroquine intracellular levels of free iron
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Figure 2: Chloroquine treatment causes intracellular accumulation
of heme and globin. (a) CD163-positive HEK cells were exposed
to 2mg/mL Hb:Hp for 12 hours in the presence or absence of
chloroquine (10 𝜇M).The image shows pellets of extensively washed
cells at the end of the treatment period. Chloroquine-treated cells
appear intensely red-brown after Hb:Hp exposure, indicating high
intracellular heme. (b) Integration of fragment-ion signal intensities
for the Hb 𝛽-chain specific peptide SAVTALWGK, as detected by
SRM. Sequences and m/z ratios of the targeted peptide fragments
are indicated. The integrated signals confirm that the Hb peptide
accumulates in the chloroquine-treated cells compared to control
cells. The insert shows VIS spectra in the range of 500 nm–650 nm
of cell lysates, showing a characteristic Hb absorption component in
the chloroquine + Hb treated cells.
are shifted towards a state of relative iron deprivation.
Accordingly, while Hb:Hp uptake stimulated mRNA induc-
tion of the principal iron exporter ferroportin in untreated
macrophages, chloroquine treatment blunts this adaptive
response, presumably by limiting iron recovery from Hb
(Figure 4(c)). Collectively, these data support our hypothesis
that chloroquine could limit the capacity of macrophages to
detoxify heme and to recycle iron.
2.5. Chloroquine Paralyzes Endocytic Hb:Hp Trafficking. As
a lysosomotropic agent, chloroquine is likely to alter the
dynamics of Hb:Hp trafficking though the endosomal-
lysosomal compartments. We performed confocal fluores-
cence microscopy to examine how chloroquine changes the
temporal and spatial relationships of endocytosed Hb:Hp
with the early endosomal marker transferrin and the
lysosome-associated-membrane-protein-1 (LAMP-1). After
15min (Figure 5(a)), we found that chloroquine favoured
colocalization of endocytosed Hb:Hp with the early endo-
somal marker transferrin, while more Hb:Hp was already
transported from early endosomes to LAMP-1-positive lyso-
somes in untreated cells (Figure 5(b)). Only in the later decay
phase, after 40min,Hb:Hpwas found to predominantly colo-
calize with lysosomal LAMP-1 in chloroquine-treated cells,
whereas, in the absence of chloroquine, Hb:Hp was largely
degraded at this later time point. Both early endosomes and
lysosomes showed uniform enlargement under chloroquine.
These data support the contention that chloroquine
interferes significantly with endocytic Hb:Hp trafficking and
degradation, presumably reducing heme access to cytoplas-
mic HO-1.
3. Discussion
Our data provide evidence that chloroquine or its derivatives
may interfere with an established pathway for Hb clear-
ance, thereby inhibiting heme detoxification and, potentially,
heme-iron recycling. Specifically, we found that chloroquine
blocks Hb:Hp degradation by paralyzing lysosomal function
and limiting heme access to HO-1, the primary enzyme of
Hb-heme catabolism.
For this study, we developed a method to track intra-
cellular globin concentration after endocytosis of Hb:Hp
complexes. Although assays by spectrophotometry might
enable Hb quantification in cells, based on the characteristic
absorption spectra of its heme moiety, quantification of the
protein itself remains challenging. Flow-cytometry assays,
as alternative methods, require fluorescent tracers, which
may alter the natural elimination rate of a target protein
or metabolically skew a protein of interest. Furthermore,
the elimination of the fluorescent tracer may disconnect
from heme/Hb elimination in the acidic and proteolytic
environment of the lysosomes.
Selected reaction monitoring (SRM) represents a pow-
erful and sensitive alternative method that allows direct
and sequence-specific protein measurement at very low-
concentration. Therefore, we developed an SRM based
method to determine relative intracellular Hb concentrations
and track the decay rate of Hb-specific peptides after endocy-
tosis. Our SRM method may be of use in other experimental
settings to evaluate hemolytic processes, tissue distribution
of free Hb, and Hb metabolism in various disease states.
Furthermore, similar assays may be developed to monitor
dynamic trafficking and clearance processes of other proteins.
Similar methods have been used previously to quantitatively
study dynamic interaction of endocytic receptors with pro-
tein ligands and to investigate protein catabolic processes
[25, 26].
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Figure 3: Chloroquine impairs Hb degradation but not primary cellular Hb uptake. (a) Fluorescent Hb:Hp (Alexa 633) uptake capacity of
chloroquine pretreated (30min) and control CD163-positive HEK cells (values given as mean ± SEM of channel fluorescence from three
independent experiments). No statistical difference was observed (𝑃 > 0.05). (b) CD163-positive HEK cells, with and without chloroquine
pretreatment (as shown in Figure 2), were incubated for 12 hours withHb:Hp 2mg/mL. After removingHb from culturemedium by extensive
washing, the cell samples were either immediately lysed or further incubated for 180min before intracellular Hb-specific peptides were
relatively quantified by SRM. The following three Hb peptides were monitored and are individually represented in the graph: SAVTALGK,
MFLSFPTTK, and LLVVYPWTQR (see Figure 1).TheHb decay is significantly less in the chloroquine-treated cells (control 0 versus 180min
𝑃 < 0.05, chloroquine-treated 0 versus 180min 𝑃 > 0.05). Data points represent mean peptide abundance values that were determined in
three independent experiments.
Under our experimental conditions, which involved drug
concentrations within the range of peak plasma concentra-
tions measured in chloroquine-treated patients [27, 28], the
agent does not impair initial endocytosis ofHb:Hp complexes
by the CD163 scavenger receptor. However, chloroquine
treatment drastically slows the decay rate of Hb. The result-
ing massive Hb accumulation is attributable to the known
lysosomotropic action of this agent. Apparently, degradation
of Hb requires an intact lysosomal system for cytoplasmic
delivery ofHb-derived heme and further catabolismbyHO-1.
Morphologically, the result of deregulated Hb trafficking
becomes apparent as a global congestive enlargement of
lysosomes that we observed by confocal microscopy. In
chloroquine-treated cells the Hb:Hp complexes are stacked
within the early endosomal compartment, reaching the lyso-
some compartment only 40-minutes after completed endo-
cytosis. Normally, trafficking of Hb:Hp complexes through
the endosomal-lysosomal compartment is largely completed
at this time point.
We have previously shown that Hb-heme internalization
by CD163 induces high levels of HO-1 mRNA and protein
expression [7, 29]. Upon treatment with chloroquine, Hb is
still internalized into the endocytic compartment by CD163
receptor, but the HO-1 expression is abolished, possibly due
to limited delivery of Hb-derived heme into the cytoplasm.
HO-1 is pivotal in preventing Hb toxicity by catabolizing
heme to the anti-inflammatory and antioxidant byproducts:
bilirubin, carbon monoxide, and ferritin [23, 24]. However, if
this protective mechanism is suppressed, susceptibility to the
oxidative and proinflammatory toxicities of extracellular Hb
may increase, particularly during acute hemolytic episodes.
It could be hypothesized that inhibition of Hb detox-
ification by chloroquine treatment could be particularly
deleterious in patients infected with chloroquine resistant
plasmodiumparasites.The 1.63-fold increased risk of cerebral
malaria and 4-fold increased risk ofmortality in chloroquine-
treated children that was observed in a study of home-
treatment strategies for febrile children in Nigeria could
endorse this hypothesis [30].
We also found that chloroquine adversely modifies
Hb:Hp triggered adaptation of iron homeostasis in human
macrophages preventing release of heme iron into the recycle
pathway. Under normal conditions, the heme-iron load,
which is imparted by endocytosis of Hb:Hp complexes,
causes a rapid downregulation of the transferrin receptor and
a concurrent induction of the iron exporter ferroportin [8].
This adaptive response assures that iron homeostasis is shifted
towards enhanced iron supply to the bone marrow, which
is a critical process in hemolytic anemia [31]. Chloroquine
treatment appears to suppress this adaptive gene regulation
and may therefore impair heme-iron recycling.
In conclusion, our studies indicate that chloroquine
interferes with the detoxification pathway of extracellular
Hb. In some conditions chloroquine treatment may therefore
aggravate the deleterious effects of hemolysis, limiting ery-
thropoietic heme-iron supply and promoting inflammation
and tissue damage in patients with malaria or autoimmune
hemolytic anemia.
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Figure 4: Chloroquine treatment attenuates the cellular HO-1 and iron metabolism response to Hb:Hp exposure. (a) Relative mRNA (left)
and protein (right, Western blot) expression levels of HO-1 in chloroquine-treated and untreated CD163-positive HEK cells after stimulation
with Hb:Hp (2mg/mL) for 8 hours (values represent mean ± SEM of at least three independent experiments). (b) Relative mRNA (left) and
protein (right, Western blot) expression levels of HO-1 in human monocyte derived macrophages after Hb:Hp (2mg/mL) exposure for 8
hours in the presence or absence of chloroquine. (c) Relative changes of transferrin receptor (TfR1) and ferroportin mRNA expression in
human monocyte derived macrophages after Hb:Hp (2mg/mL) exposure for 8 hours in the presence or absence of chloroquine. All mRNA
changes are given relative to control cells (data indicate mean ± SEM of at least three independent experiments).
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Figure 5: Chloroquine impairs Hb:Hp trafficking through the endosomal-lysosomal compartment. (a) CD163-positive HEK cells incubated
15min after endocytosis with Alexa 594-labeled Hb:Hp complexes and Alexa 488-labeled transferrin, with and without chloroquine
pretreatment. The proportion of endocytosed Hb:Hp complexes colocalizing with the early endosomal compartment (transferrin-positive)
increases substantially after chloroquine exposure. (b) CD163-positive HEK cells incubated for 15min (upper two rows) or 40min (lower
two rows) after endocytosis with Alexa 594-labeled Hb:Hp complexes. The lysosomal compartment is stained with anti-LAMP-1 antibody
and Alexa 488-labeled secondary antibody. Early colocalization of Hb:Hp complexes in the lysosomal (LAMP-1) compartment after 15min is
considerably reduced by pretreatment with chloroquine. In contrast, after 40min, chloroquine pretreatment leads to marked accumulation
of Hb:Hp complexes in the lysosomes. Optical magnification of all images is 630x. DAPI-stained nuclei are blue, and scale bars are spaced at
5𝜇m. The percentage of colocalization is shown in the graphs on the right with black bars indicating control cells and gray bars indicating
chloroquine-treated cells; 𝑛 = 4-5 images per condition that were recorded on independent samples.
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4. Material and Methods
4.1. HEKCells Transfection and Culture. Human-embryonic-
kidney- (HEK-) 293 cells (Invitrogen, Basel, Switzerland)
were cultured in DMEM (Invitrogen) containing 10% FCS
(Invitrogen). CD163-expressing lentiviral-transduced HEK-
293 cells were generated as described elsewhere [5] and
maintained with 5𝜇g/mL blasticidin (Invitrogen), which was
removed from cultures at least one cell passage prior to
experiments.
4.2. Macrophage Isolation. Human-blood-derived mono-
cytes were prepared from buffy coats of healthy donors, as
purchased from the Swiss Red Cross Blood Bank (Swiss Red
Cross) and already described [32]. These cells were cultured
in Iscove modified Dulbecco medium (Invitrogen), supple-
mented by 10% heat-inactivated, pooled human serum hav-
ing negligible residual free Hb by design. Written informed
consent was obtained from all donors, in accordance with the
Declaration of Helsinki, and all the work was approved by the
ethics review board of the Canton of Zurich.
4.3. Proteomic Sample Preparation and TSQ Mass-Spectrom-
etry. Total cellular protein was extracted using CelLytic-M
reagent (Sigma-Aldrich) supplemented by Complete Mini
Protease Inhibitor (Roche Diagnostics). After three freeze-
thaw cycles, cellular debris was removed by a 30-minute
centrifugation (16000×g).
Theprotein concentration of each samplewas determined
using Bradford assay (Bio-Rad, Hercules, CA, USA). Samples
were precipitated by adding TCA (10% final concentration)
and incubated on ice for 20min. Following centrifugation
(14000×g), the supernatant was removed, and the pellets
were triple-washed in ice-cold acetone. Afterward, they were
dried 5min at 95∘C and reconstituted in 0.1% RapiGest
(Waters). Disulfide bonds were reduced by DTT additive and
finally blocked by treatment with iodoacetamide. The pellets
were next subjected to overnight digestion by trypsin (1 : 10
ratio, trypsin to protein) at 37∘C. Lyophilized peptide mix-
tures were ultimately dissolved in 5% ACN and 0.1% formic
acid for loading onto a 5 𝜇m C18 column (PicoFrit Column
Hyp. Gold, AQ 5 𝜇m, 75𝜇m × 100mm, New Objective Inc.).
A TSQ Vantage Triple Quadrupole mass spectrometer
(Thermo Fisher Scientific, Waltham, MA, USA), equipped
with a nanoelectrospray ionization source, was used for SRM
measurements. Chromatographic peptide separations were
performed on an Eksigent 1D Nano-LC system (Eksigent
Technologies), applying a 55min gradient from 5 to 50% v/v
acetonitrile in water, both amended with 0.1% v/v formic
acid. The LC operational flow rate was 500 nLmin−1. Mass-
spectrometry was done in SRM mode; Q1 and Q3 were set
at resolutions 0.2 and 0.7Da, respectively. A spray voltage of
+1400V was used with a heated ion transfer capillary setting
of 120∘C for desolvation. A 20ms dwell time was set, with
0.002m/z scan width.
4.4. Analysis by Selected Reaction Monitoring. SRM meth-
ods were developed and optimized as described elsewhere
[33–35]. Tryptic peptides lackingmethionine or cysteinewere
measured, and transitions (for three peptides per protein)
were selected considering first maximum signal intensities
observed during LC-MS/MS, with further refinement with
respect to signal-to-noise measurements during the SRM
trials. SRM peak areas were calculated by using Pinpoint
software (Thermo Fisher Scientific, Waltham, MA, USA).
All SRM measurements were performed on three biologic
replicates.
4.5. Quantitative Real-Time Reverse Transcription-Polymerase
Chain Reaction (RT-PCR). Real-time RT-PCR was per-
formedon aFast Real-TimePCRSystem Instrument (Applied
Biosystems) using TaqMan reverse transcription and SYBR
Green master mix PCR reagents (Applied Biosystems) as
described. Gene-specific quantitative data were corrected for
HPRT mRNA abundance in the respective samples and are
expressed as fold expression relative to the control.
4.6. Western Blot Analysis. Western blots were performed
using standard techniques and a single primary HO-1 anti-
body (SPA-896; Stressgen). Sample loading was adjusted for
equal protein per lane after measurement of the protein con-
centration by Bradford assay (Bio-Rad, Hercules, CA, USA).
Thehorseradish peroxidase-conjugated secondary antibodies
(Amersham Biosciences) used for detection were diluted
1 : 10000. Blots were developed with ECL Plus Western blot-
ting detection reagent (AmershamBiosciences) and analyzed
on a ChemiDoc XRS system with Quantity One 1-D Analysis
software, version 4.5.0 (Bio-Rad).
4.7. Analysis of Fluorescent Hb:Hp Uptake. CD163-trans-
ducedHEK-293were incubated for 30min at 37∘CwithAlexa
633-labeled Hb:Hp (3𝜇g/mL) [32]. The cells were washed
with EDTA containing buffer and resuspended in phosphate-
buffered saline (PBS) for analysis by a FACSCalibur (Becton
Dickinson). Data were analyzed with CellQuest (Becton
Dickinson).
4.8. Confocal Fluorescence Microscopy. For fluorescence
microscopy, HEK cells were cultured on baked (4 h at
220∘C), endotoxin-free, sterile, round, 12mm glass cover-
slips (Hecht-Assistent, Germany), placed in 24-cluster wells,
and pretreated 2 h before examination with 6.25mcg/cm2
poly-D-lysine hydrobromide (BD Biosciences, San Jose, CA,
USA). Pretreatment with chloroquine (10𝜇M) lasted 12 h.
Fluorescent-labeled Hb:Hp complexes (with or without flu-
orescent transferrin) required a 15min incubation in cell
culture medium containing 10% FCS. To determine subcel-
lular localization of Hb:Hp 15 or 40min after endocytosis,
the medium was changed, and a second incubation (with or
without transferrin) followed in the absence of fluorescent
Hb:Hp complexes. Labeling of Hp (Sigma Chemical Co.)
was done using Alexa 594 protein-labeling kit (Molecular
Probes, Eugene, OR, USA). Hb:Hp complexes were generated
by combining Hb and fluorescent Hp at a 1 : 1 molar ratio,
10min before examination. Hb:Hp complexes were employed
at 10 𝜇g/mL concentration. Transferrin was labeled using the
Oxidative Medicine and Cellular Longevity 9
Alexa 488 protein-labeling kit and employed at 20 𝜇g/mL
concentration. Finally, the cells were triple-washed with PBS,
pH 7.4 (Sigma Chemical Co., St. Louis, MO, USA), fixed
15min in PBS with 2.5% paraformaldehyde, and permeabi-
lized for 5min at room temperature in 0.1% Triton X-100
(Sigma Chemical Co.) and PBS. After washing, nonspecific
binding sites were blocked for 1 h in 10% goat serum and PBS,
supplemented with 1% bovine serum albumin ((BSA) Sigma
Chemical Co.), again at room temperature.
Staining of LAMP-1 was accomplished by incubation
1 h at room temperature with mouse anti-LAMP-1 antibody
(RDI Research Diagnostics, Concord, MA, USA), diluted
1 : 800 in PBS supplemented by 1% goat serum and 0.1%
BSA. Alexa Fluor 488 goat anti-mouse IgG (Molecular
Probes) served as a secondary antibody, using 10 𝜇g/mL 4,6-
diamidino-2-phenylindole ((DAPI) Sigma Chemical Co.) as
a nuclear counterstain. After three washes in PBS, cover-
slips were applied using ProLong Gold antifade reagent-
mounting medium (Molecular Probes). Optical sections at
0.125𝜇m were viewed under a Leica SP5 confocal laser-
scanning microscope (Leica, Heidelberg, Germany), using
default magnification of 630x. Images were imported into
Imaris software, version 6.1.2 (Bitplane Scientific Software,
Zurich, Switzerland).
The extent of colocalization was quantified on the basis
of intensity per colocalization module in Imaris. To differ-
entiate fluorescent Hb:Hp (red channel) colocalization with
transferrin or LAMP-1 (both green channel), the red channel
contribution to colocalized areas was analyzed using a fixed
threshold of 127.5 in both channel histograms.
4.9. Statistical Analysis. Data were analyzed with GraphPad
Prism version 4.0. We used an unpaired 2-tailed Student’s 𝑡-
test for comparisons of groups, with ANOVA where applica-
ble. 𝑃 values < 0.05 were considered statistically significant.
Abbreviations
Hb: Hemoglobin
Hp: Haptoglobin
HO-1: Heme-oxygenase-1
GAPDH: Glyceraldehyde-3-phosphate dehydrogenase
LAMP-1: Lysosomal-associated-membrane-protein-1
SRM: Single reaction monitoring
ACN: Acetonitrile.
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